BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 17468774)

  • 1. A randomized comparison of empiric or pre-emptive antibiotic therapy after hematopoietic stem cell transplantation.
    Slavin MA; Grigg AP; Schwarer AP; Szer J; Spencer A; Sainani A; Thursky KA; Roberts AW
    Bone Marrow Transplant; 2007 Jul; 40(2):157-63. PubMed ID: 17468774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime.
    Raad II; Escalante C; Hachem RY; Hanna HA; Husni R; Afif C; Boktour MR; Whimbey EE; Kontoyiannis D; Jacobson K; Kantarjian H; Levett LM; Rolston KV
    Cancer; 2003 Sep; 98(5):1039-47. PubMed ID: 12942573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fever and neutropenia in pediatric hematopoietic stem cell transplant patients.
    Mullen CA; Nair J; Sandesh S; Chan KW
    Bone Marrow Transplant; 2000 Jan; 25(1):59-65. PubMed ID: 10654016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infectious complication in 314 patients after high-dose therapy and autologous hematopoietic stem cell transplantation: risk factors analysis and outcome.
    Gil L; Styczynski J; Komarnicki M
    Infection; 2007 Dec; 35(6):421-7. PubMed ID: 17926001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the value of empiric vancomycin administration in febrile neutropenia occurring after autologous peripheral blood stem cell transplants.
    Koya R; Andersen J; Fernandez H; Goodman M; Spector N; Smith R; Hanlon J; Cassileth PA
    Bone Marrow Transplant; 1998 May; 21(9):923-6. PubMed ID: 9613785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies.
    Cherif H; Björkholm M; Engervall P; Johansson P; Ljungman P; Hast R; Kalin M
    Scand J Infect Dis; 2004; 36(8):593-600. PubMed ID: 15370671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of early neutropenic fever, with or without bacterial infection, is still a significant complication after reduced-intensity stem cell transplantation.
    Hori A; Kami M; Kim SW; Chizuka A; Kojima R; Imataki O; Sakiyama M; Hamaki T; Onishi Y; Usubuchi N; Kishi Y; Murashige N; Tajima K; Miyakoshi S; Heike Y; Masuo S; Taniguchi S; Takaue Y
    Biol Blood Marrow Transplant; 2004 Jan; 10(1):65-72. PubMed ID: 14752781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical impact of antibacterial prophylaxis and cycling antibiotics for febrile neutropenia in a hematological malignancy and transplantation unit.
    Craig M; Cumpston AD; Hobbs GR; Devetten MP; Sarwari AR; Ericson SG
    Bone Marrow Transplant; 2007 Apr; 39(8):477-82. PubMed ID: 17322937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Febrile neutropenia in allogeneic and autologous peripheral blood stem cell transplantation and conventional chemotherapy for malignancies.
    Celebi H; Akan H; Akçağlayan E; Ustün C; Arat M
    Bone Marrow Transplant; 2000 Jul; 26(2):211-4. PubMed ID: 10918433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Febrile neutropenia in paediatric peripheral blood stem cell transplantation, in -vitro sensitivity data and clinical response to empirical antibiotic therapy.
    Ansari SH; Nasim S; Ahmed A; Irfan M; Ishaque A; Farzana T; Panjwani VK; Taj M; Shamsi TS
    J Coll Physicians Surg Pak; 2006 Nov; 16(11):704-8. PubMed ID: 17052420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cefepime as an empiric treatment of febrile neutropenia in patients after high dose therapy and autologous stem cell transplantation].
    Zikesoá E; Hnátková M; Vacková B; Jedlicková A; Klener P; Trnený M
    Cas Lek Cesk; 2006; 145(5):383-6, 388-9. PubMed ID: 16755776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination of 4th-generation cephalosporin + aminoglycosides: comparative study.
    Tamura K; Matsuoka H; Tsukada J; Masuda M; Ikeda S; Matsuishi E; Kawano F; Izumi Y; Uike N; Utsunomiya A; Saburi Y; Shibuya T; Imamura Y; Hanada S; Okamura S; Gondoh H;
    Am J Hematol; 2002 Dec; 71(4):248-55. PubMed ID: 12447952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dental health and viridans streptococcal bacteremia in allogeneic hematopoietic stem cell transplant recipients.
    Graber CJ; de Almeida KN; Atkinson JC; Javaheri D; Fukuda CD; Gill VJ; Barrett AJ; Bennett JE
    Bone Marrow Transplant; 2001 Mar; 27(5):537-42. PubMed ID: 11313689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Panipenem versus cefepime as empirical monotherapy in adult cancer patients with febrile neutropenia: a prospective randomized trial.
    Kwon KT; Cheong HS; Rhee JY; Wi YM; Ryu SY; Heo ST; Moon CS; Ki HK; Kim KH; Jung CW; Peck KR; Song JH
    Jpn J Clin Oncol; 2008 Jan; 38(1):49-55. PubMed ID: 18203711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of obtaining blood cultures in febrile neutropenic patients undergoing bone marrow transplantation.
    Serody JS; Berrey MM; Albritton K; O'Brien SM; Capel EP; Bigelow SH; Weber DJ; Gabriel ; Wiley JM; Schell MJ; Gilligan PH; Shea TC
    Bone Marrow Transplant; 2000 Sep; 26(5):533-8. PubMed ID: 11019843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial therapy of febrile complications after high-dose chemo-/radiotherapy and autologous hematopoietic stem cell transplantation--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).
    Bertz H; Auner HW; Weissinger F; Salwender HJ; Einsele H; Egerer G; Sandherr M; Schüttrumpf S; Südhoff T; Maschmeyer G;
    Ann Hematol; 2003 Oct; 82 Suppl 2():S167-74. PubMed ID: 13680166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Piperacillin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial.
    Harter C; Schulze B; Goldschmidt H; Benner A; Geiss HK; Hoppe-Tichy T; Ho AD; Egerer G
    Bone Marrow Transplant; 2006 Feb; 37(4):373-9. PubMed ID: 16400334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imipenem/cilastatin with or without glycopeptide as initial antibiotic therapy for recipients of autologous stem cell transplantation: results of a Spanish multicenter study.
    de la Rubia J; Montesinos P; Martino R; Jarque I; Rovira M; Vázquez L; López J; Batlle M; de la Cámara R; Juliá A; Lahuerta JJ; Debén G; Díaz J; García R; Sanz MA
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):512-6. PubMed ID: 19285640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-risk febrile neutropenia in Auckland 2003-2004: the influence of the microbiology laboratory on patient treatment and the use of pathogen-specific therapy.
    Ritchie S; Palmer S; Ellis-Pegler R
    Intern Med J; 2007 Jan; 37(1):26-31. PubMed ID: 17199841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant.
    Weinstock DM; Conlon M; Iovino C; Aubrey T; Gudiol C; Riedel E; Young JW; Kiehn TE; Zuccotti G
    Biol Blood Marrow Transplant; 2007 May; 13(5):615-21. PubMed ID: 17448922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.